LEDERMAN SETH 4

What Happened
Seth Lederman, CEO of Tonix Pharmaceuticals (TNXP), reported a purchase of 15,000 shares on 2026-03-18 at $14.89 per share, for a total transaction value of $223,350. The Form 4 marks this as a purchase (code P), which is a direct acquisition of common stock rather than a sale or option exercise.

Key Details

• Transaction date: 2026-03-18
• Transaction type: Open market or private purchase (Code P)
• Price and size: 15,000 shares at $14.89 per share; total $223,350
• Shares owned after transaction: Not disclosed in this filing
• Footnote: F1 — reporting person may be deemed a control person of this entity
• Filing timeliness: Form filed with the SEC on 2026-03-18 (appears to be filed same day as the reported transaction)

Context
A direct purchase by a CEO is typically more informative to investors than routine sales because it represents the insider adding to a position. This report is factual disclosure of the purchase; it does not indicate the insider’s motivations.